Figure 1. CPX-351 vs 7+3 (7 days of cytarabine and 3 days of daunorubicin). OS for patients with secondary AML. Numbers in parentheses represent confidence intervals. Reprinted from Ravandi et al12 with permission.
Figure 1

CPX-351 vs 7+3 (7 days of cytarabine and 3 days of daunorubicin). OS for patients with secondary AML. Numbers in parentheses represent confidence intervals. Reprinted from Ravandi et al12  with permission.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal